These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 22074425)

  • 21. Nitroreductase-based GDEPT.
    Denny WA
    Curr Pharm Des; 2002; 8(15):1349-61. PubMed ID: 12052212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucuronides in anti-cancer therapy.
    Chen X; Wu B; Wang PG
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):139-50. PubMed ID: 12678908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted prodrug approaches for hormone refractory prostate cancer.
    Aloysius H; Hu L
    Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prodrug strategies in cancer therapy.
    Denny WA
    Eur J Med Chem; 2001; 36(7-8):577-95. PubMed ID: 11600229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
    Leu YL; Chen CS; Wu YJ; Chern JW
    J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy.
    Tietze LF; von Hof JM; Krewer B; Müller M; Major F; Schuster HJ; Schuberth I; Alves F
    ChemMedChem; 2008 Dec; 3(12):1946-55. PubMed ID: 19021160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Photoactivatable prodrugs of highly potent duocarmycin analogues for a selective cancer therapy.
    Tietze LF; Müller M; Duefert SC; Schmuck K; Schuberth I
    Chemistry; 2013 Jan; 19(5):1726-31. PubMed ID: 23225610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer chemotherapy and drug metabolism.
    Riddick DS; Lee C; Ramji S; Chinje EC; Cowen RL; Williams KJ; Patterson AV; Stratford IJ; Morrow CS; Townsend AJ; Jounaidi Y; Chen CS; Su T; Lu H; Schwartz PS; Waxman DJ
    Drug Metab Dispos; 2005 Aug; 33(8):1083-96. PubMed ID: 16049130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Painting the target around the arrow: two-step prodrug therapies from a carbohydrate chemist's perspective.
    Houston TA
    Curr Drug Deliv; 2007 Oct; 4(4):264-8. PubMed ID: 17979645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-activated prodrugs--a new approach to cancer therapy.
    Denny WA
    Cancer Invest; 2004; 22(4):604-19. PubMed ID: 15565818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme/abzyme prodrug activation systems: potential use in clinical oncology.
    Nishi Y
    Curr Pharm Des; 2003; 9(26):2113-30. PubMed ID: 14529409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.
    Legigan T; Clarhaut J; Tranoy-Opalinski I; Monvoisin A; Renoux B; Thomas M; Le Pape A; Lerondel S; Papot S
    Angew Chem Int Ed Engl; 2012 Nov; 51(46):11606-10. PubMed ID: 22996951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new paclitaxel prodrug for use in ADEPT strategy.
    Bouvier E; Thirot S; Schmidt F; Monneret C
    Org Biomol Chem; 2003 Oct; 1(19):3343-52. PubMed ID: 14584798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prodrug applications for targeted cancer therapy.
    Giang I; Boland EL; Poon GM
    AAPS J; 2014 Sep; 16(5):899-913. PubMed ID: 25004822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Highly selective glycosylated prodrugs of cytostatic CC-1065 analogues for antibody-directed enzyme tumor therapy.
    Tietze LF; Herzig T; Fecher A; Haunert F; Schuberth I
    Chembiochem; 2001 Oct; 2(10):758-65. PubMed ID: 11948858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
    Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
    J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzyme and proton-activated prodrugs for a selective cancer therapy.
    Tietze LF; Feuerstein T
    Curr Pharm Des; 2003; 9(26):2155-75. PubMed ID: 14529411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prodrugs in genetic chemoradiotherapy.
    Patterson AV; Saunders MP; Greco O
    Curr Pharm Des; 2003; 9(26):2131-54. PubMed ID: 14529410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.
    Khatri A; Russell PJ
    Discov Med; 2007 Feb; 7(37):39-45. PubMed ID: 17343804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of prodrugs for enzyme-mediated, tumor-selective therapy.
    Yoon KJ; Potter PM; Danks MK
    Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.